R. Jonathan Henderson, MD, argues that the goal of ADT should be to achieve and maintain the lowest levels of T possible in prostate cancer patients. The FDA-recommended target low of 50 ng/dL originates from constraints of outdated technology, and multiple studies indicate that there is a benefit to patients when T-levels fall below 20 ng/dL.Read More
R. Jonathan Henderson, MD
Regional Urology, LLC
R. Jonathan Henderson, MD, obtained a Bachelor of Science Degree at LSU in Baton Rouge in microbiology. After receiving his M.D. at LSU Medical Center in Shreveport, he completed his internship and residency in Urology at LSUMC Hospital. During this time, he authored a number of papers and presentations. Dr. Henderson spent the next six years in practice in Alabama where he specialized in treating disorders of the female bladder and laparoscopy. During this time, he served as a representative of Alabama to the Southeastern Section of the American Urology Association. He also served as an assistant clinical professor of Urology at the University of Alabama. Dr. Henderson is certified by the American Board of Urology. He is a member of the American Urologic Association, Shreveport Medical Society, Louisiana State Medical Society, the Society of Laparoscopic Surgeons, and the Alpha Omega Alpha Medical Honor Society. He has been on the LUGPA Board of Directors since 2011 and is currently serving as Secretary.
Articles by R. Jonathan Henderson, MD
The LUGPA Alternative Payment Model (APM) on Newly Diagnosed PCa and the Role of Active Surveillance
Posted by R. Jonathan Henderson, MD | Apr 2018
R. Jonathan Henderson, MD, summarizes the Large Urology Group Practice Association’s (LUGPA’s) efforts to develop an alternative payment model (APM) for urologists treating newly diagnosed prostate cancer patients. He explains the roadblocks to reaching this goal, including conflicts with the Physician-Focused Payment Model Technical Advisory Committee (PTAC).Read More